Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $1.21, $0.10 better than the analyst estimate of $1.11. Revenue for the quarter came in at $466.8 million versus the consensus estimate of $441.64 million.

GUIDANCE:

Charles River Laboratories sees FY2017 EPS of $5.00-$5.10, versus the consensus of $5.05.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.